4D Molecular Therapeutics, Inc.
4D Molecular Therapeutics, Inc. (FDMT) Stock Ownership
Institutional vs insider vs public ownership from 13F and float data — top holders, activity, and insider trades below.
SEC 13F · FMP · FDMT · as of Mar 31, 2025
Ownership Breakdown
126
Institutional Holders
▼ 21 vs Q4
$140.90M
Total Inst. Value
▼ $120.76M vs Q4
52.28M
Shares Outstanding
freeFloat 74.30%
43.09M
13F Shares Held
▼ 3.76M vs Q4
Institutional ownership = 13F shares ÷ total outstanding. Insider % = 100 − free float. Public % = free float − institution %. Data: FMP /symbol-positions-summary + /shares-float + SEC EDGAR.
Top Institutional Holders
FDMT largest shareholders · institutional ownership
Q1 2025 · SEC 13F
Showing top 10 holders
| Holder | Shares | % Owned | Weight | Value | Reported | Change |
|---|---|---|---|---|---|---|
RA CAPITAL MANAGEMENT, L.P. biological products, (no diagnostic substances) | 4.56M | 8.19% | 8.19% | $14.74B | May 15, 2025 | — held |
BVF INC/IL biological products, (no diagnostic substances) | 4.56M | 8.18% | 8.18% | $14.73B | May 15, 2025 | ▲ 1.89M |
BLACKROCK, INC. biological products, (no diagnostic substances) | 4.55M | 8.16% | 8.16% | $14.69B | May 2, 2025 | ▼ 374.2K |
GOLDMAN SACHS GROUP INC biological products, (no diagnostic substances) | 4.17M | 7.48% | 7.48% | $13.46B | Jun 27, 2025 | ▼ 106.6K |
VANGUARD GROUP INC biological products, (no diagnostic substances) | 2.76M | 4.95% | 4.95% | $8.91B | May 9, 2025 | ▼ 103.0K |
NOVO HOLDINGS A/S biological products, (no diagnostic substances) | 1.95M | 3.50% | 3.50% | $6.30B | May 15, 2025 | ▲ 450.0K |
JANUS HENDERSON GROUP PLC biological products, (no diagnostic substances) | 1.89M | 3.39% | 3.39% | $6.87B | May 15, 2025 | ▼ 360.3K |
MORGAN STANLEY biological products, (no diagnostic substances) | 1.78M | 3.19% | 3.19% | $5.74B | May 15, 2025 | ▼ 86.3K |
MILLENNIUM MANAGEMENT LLC biological products, (no diagnostic substances) | 1.63M | 2.93% | 2.93% | $5.28B | May 15, 2025 | ▲ 213.3K |
FEDERATED HERMES, INC. biological products, (no diagnostic substances) | 1.25M | 2.24% | 2.24% | $4.04B | May 8, 2025 | ▲ 1.25M |
Data from SEC Form 13F filings. Ownership bar normalised to largest holder. Change flags: isNew / isSoldOut / changeInSharesNumber (FMP extract-analytics/holder).
Institutional Activity
Q1 2025 vs prior quarter
Q1 2025
18
Increased
+5.76M shares1
New Positions
first time holders27
Decreased
−5.11M shares0
Sold Out
fully exitedNet shares change (top 50)
+650.6K
+5.76M / −5.11M
Net new holders
-8
1 new / 0 exited
Based on top 50 institutional holders by position size. Fields: isNew, isSoldOut, changeInSharesNumber (FMP extract-analytics/holder, limit=50).
Insider Buying vs Selling
FDMT insider trading · insider activity
Source: SEC Form 4
Insiders have been primarily selling shares recently. Selling may be driven by pre-scheduled Rule 10b5-1 plans rather than negative sentiment.
0
Buy transactions
1
Sell transactions
0.00
Buy/Sell ratio
$0M
Total disposed
Recent Insider Transactions
Showing 10 most recent · Common Stock only
| Name · Role | Date | Type | Shares | Price | Value | After Trans. | Filing |
|---|---|---|---|---|---|---|---|
Kirn David See Remarks | Jun 1, 2026 | Sale | 1,922 | $10.02 | $19.3K | 1.06M | Form 4 ↗ |
Kirn David Chief Executive Officer | Mar 25, 2026 | Award | 750,000 | $9.88 | $7.41M | 750.0K | Form 4 ↗ |
Bizily Scott Chief Legal Officer | Mar 25, 2026 | Award | 217,000 | $9.88 | $2.14M | 217.0K | Form 4 ↗ |
Simms Christopher Paul See Remarks | Mar 25, 2026 | Award | 219,000 | $9.88 | $2.16M | 219.0K | Form 4 ↗ |
Gupta Ashoo VP, Finance and Controller | Mar 20, 2026 | Sale | 80 | $8.61 | $688.8 | 47.1K | Form 4 ↗ |
Gupta Ashoo VP, Finance and Controller | Mar 20, 2026 | Sale | 310 | $8.61 | $2.7K | 46.9K | Form 4 ↗ |
SBLENDORIO GLENN director | Jan 5, 2026 | Award | 45,000 | $7.30 | $328.5K | 45.0K | Form 4 ↗ |
Gupta Ashoo VP, Finance and Controller | Dec 20, 2025 | Sale | 79 | $8.68 | $685.72 | 46.4K | Form 4 ↗ |
Gupta Ashoo VP, Finance and Controller | Dec 20, 2025 | Sale | 310 | $8.68 | $2.7K | 46.2K | Form 4 ↗ |
Source: /insider-trading/search (FMP stable). Buy/Sell direction: acquisitionOrDisposition A=Buy, D=Sell. RSU vesting (M-Exempt) excluded from sentiment bar. All data from SEC EDGAR public filings.
About institutional & insider ownership
4D Molecular Therapeutics, Inc. (FDMT) is primarily owned by institutional investors, who hold approximately 82.4% of total shares outstanding. Company insiders own approximately 25.70%, while retail and public investors account for the remaining 0.00%.
The largest institutional shareholder of 4D Molecular Therapeutics, Inc. is RA CAPITAL MANAGEMENT, L.P., holding approximately 4.56 million shares — equal to 8.19% of outstanding shares — as of March 31, 2025.
A total of 126 institutional investors currently hold FDMT stock, with a combined institutional value of approximately $140,901,844 as of the most recent 13F filing period.
Frequently asked questions
FDMT ownership4D Molecular Therapeutics, Inc. (FDMT) is primarily owned by institutional investors, who hold approximately 82.4% of shares. The largest shareholder is RA CAPITAL MANAGEMENT, L.P. with a 8.19% stake. Company insiders hold 25.70%. Data sourced from SEC Form 13F as of March 31, 2025.